Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    50,733.04
    -204.24 (-0.40%)
     

  • CMC Crypto 200

    1,325.83
    +48.85 (+3.83%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
BRANDS:

Meet one of the UK’s largest unknown start-ups

Video editing platform Veed has grown to 10 million users

BUZZ-AstraZeneca: gains after dodging bullet on diabetes drug

Reuters - UK Focus

** Shares (Berlin: DI6.BE - news) up 1.5 pct as US FDA panel decides not to recommend any restrictions on prescribing its diabetes drug Onglyza, despite a risk of heart failure linked to the medicine

** A tougher stance could have jeopardised sales, but Deutsche Bank (Xetra: 514000 - news) analyst Richard Parkes says he is leaving unchanged his forecast for Onglyza sales of $776 mln in 2015 growing to $1.25 bln in 2018, or 5% of group sales

** Stock also supported by news that the experimental immune system-boosting drug tremelimumab has won "orphan" drug status in US for treating malignant mesothelioma, a rare type of cancer

(RM (LSE: RM.L - news) : ben.hirschler.thomsonreuters.com@reuters.net)